What Analysts Are Saying About Quest Diagnostics Stock
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Quest Diagnostics (NYSE:DGX), with recent ratings showing a mix of bullish and indifferent sentiments. The average 12-month price target has increased by 5.32% to $155.57. Analysts have raised their price targets, reflecting positive sentiment towards the company's financial performance.
August 27, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics has received mixed analyst ratings, with a recent increase in the average 12-month price target to $155.57, indicating positive sentiment. Analysts have raised their price targets, reflecting confidence in the company's financial performance.
The increase in the average price target and the positive adjustments by multiple analysts suggest a favorable outlook for Quest Diagnostics. The company's strong financial metrics, such as net margin and ROE, support this sentiment. The lack of bearish ratings further indicates a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100